NRX Pharmaceuticals (NRXP) Other Accumulated Expenses (2020 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Other Accumulated Expenses of $69000.0 for Q1 2026, down 64.8% year-over-year from $196000.0 in Q1 2025, and up 3350.0% quarter-over-quarter from $2000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Other Accumulated Expenses for 7 consecutive years, with $69000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 64.8% year-over-year to $69000.0; the TTM figure through Mar 2026 stood at $69000.0 (down 64.8% YoY), while the FY2025 annual figure was $2000.0, down 99.57% from the prior year.
- Other Accumulated Expenses rose to $69000.0 in Q1 2026 per NRXP's latest filing, from $2000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.6 million in Q3 2022 and bottomed at $2000.0 in Q4 2025.
- Historically, Other Accumulated Expenses has averaged $537647.1 across 5 years, with a median of $300000.0 in 2022.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 480.25% — and 2025, when it slumped 99.57%.
- NRX Pharmaceuticals' Other Accumulated Expenses stood at $974000.0 in 2022, then tumbled by 91.68% to $81000.0 in 2023, then jumped by 480.25% to $470000.0 in 2024, then plunged by 99.57% to $2000.0 in 2025, then jumped by 3350.0% to $69000.0 in 2026.
- Business Quant data shows NRXP's Other Accumulated Expenses at $69000.0 in Q1 2026, $2000.0 in Q4 2025, and $98000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 196,000.00 |
| Dec 31, 2024 | 470,000.00 |
| Sep 30, 2024 | 240,000.00 |
| Jun 30, 2024 | 213,000.00 |
| Mar 31, 2024 | 992,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | 974,000.00 |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | 300,000.00 |
| Mar 31, 2022 | 757,000.00 |
| Dec 31, 2021 | 1.06 Mn |
| Sep 30, 2021 | 625,139.00 |
| Jun 30, 2021 | 826,442.00 |